The immunotherapy Foundation supports research and programming to treat, and ultimately eradicate, HPV-driven cancers. IF works directly with world-class researchers to accelerate the discovery and development of new and improved immunotherapies for patients, by translating multiple research projects into the clinical setting and creating a robust portfolio of preclinical immunotherapies and award-winning research at the University of California.